Initial Treatment for Constipation

First-Line Treatment Approach

• The American Gastroenterological Association recommends starting with polyethylene glycol (PEG) 17g once daily as first-line pharmacological therapy, combined with increased fluid intake and physical activity when appropriate 1
• The National Comprehensive Cancer Network suggests that stimulant laxatives (senna or bisacodyl 10-15mg, 2-3 times daily) are equally appropriate as first-line therapy, particularly for opioid-induced constipation 2, 3
• Milk of magnesia 1 oz twice daily is an inexpensive alternative osmotic agent with comparable efficacy 1
• All of these first-line agents cost approximately $1 or less per day 1

Critical Initial Assessment

• The American Gastroenterological Association recommends ruling out fecal impaction via digital rectal examination before starting treatment 1, 2
• The National Comprehensive Cancer Network suggests ruling out bowel obstruction and metabolic causes such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus before starting treatment 2
• A medication review to discontinue or adjust constipating medications when feasible is recommended by the American Gastroenterological Association and the National Comprehensive Cancer Network 1, 2
• A complete blood count is the only laboratory test routinely recommended, with metabolic panels having low diagnostic utility unless other clinical features warrant them 1

Treatment Approach for Opioid-Induced Constipation

• The National Comprehensive Cancer Network and the Annals of Oncology recommend that all patients receiving opioid analgesics should be prescribed a concomitant laxative prophylactically, unless contraindicated by pre-existing diarrhea 2, 3
• Osmotic or stimulant laxatives are preferred over fiber for opioid-induced constipation, according to the Annals of Oncology 3

Treatment Goal and Adjustment

• The National Comprehensive Cancer Network suggests aiming for one non-forced bowel movement every 1-2 days, not necessarily daily bowel movements 2
• If constipation persists despite first-line therapy, adding a second laxative such as rectal bisacodyl once daily, lactulose, magnesium hydroxide, or magnesium citrate is recommended by the American Gastroenterological Association and the National Comprehensive Cancer Network 1, 2, 3
• Caution is advised when using magnesium salts in patients with renal impairment due to the risk of hypermagnesemia, according to the Annals of Oncology 3

Management of Constipation

Initial Assessment and Management

• The National Comprehensive Cancer Network recommends starting with a stimulant laxative (senna or bisacodyl 10-15 mg, 2-3 times daily) as first-line therapy, with the goal of achieving one non-forced bowel movement every 1-2 days 4, 5
• Before initiating treatment, assess for and rule out fecal impaction, bowel obstruction, and metabolic causes such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus 4, 5

Stepwise Treatment Algorithm

• The National Comprehensive Cancer Network suggests that evidence shows adding stool softeners like docusate to senna provides no additional benefit 4, 5
• Lifestyle modifications, including increasing fluid intake and physical activity when appropriate, are recommended 4, 5
• Dietary fiber should be considered only if the patient has adequate fluid intake (at least 2 liters daily) 6
• Supplemental medicinal fiber (like psyllium/Metamucil) is unlikely to control medication-induced constipation and is not recommended 7, 8

Second-Line Treatment

• If constipation persists, add one of the following osmotic or additional stimulant laxatives: polyethylene glycol (PEG), lactulose, magnesium hydroxide, magnesium citrate, or rectal bisacodyl 4, 5, 8, 9, 10

Third-Line Treatment

• If gastroparesis is suspected, add metoclopramide 10-20 mg, 2-3 times daily as a prokinetic agent 4, 5, 9

Fourth-Line Treatment

• For persistent constipation unresponsive to standard laxatives, consider newer secretagogues such as linaclotide, lubiprostone, or plecanatide 9, 5, 10

Key Clinical Pitfalls to Avoid

• Do not rely on fiber supplements alone, as they are ineffective for medication-induced constipation without adequate hydration 7, 8
• Do not add stool softeners to stimulant laxatives, as evidence shows no additional benefit 4, 5
• Reassess for impaction or obstruction if constipation persists despite treatment 4, 8
• Consider the gastroparesis component, as GLP-1 agonists like Mounjaro slow gastric emptying, making prokinetic agents particularly relevant 4, 9

Treatment Goals

• Aim for one non-forced bowel movement every 1-2 days rather than daily bowel movements 4, 5, 8, 9

Constipation Management Guidelines

Medication Considerations

• The National Comprehensive Cancer Network recommends reviewing and discontinuing constipating medications, including antacids, anticholinergics, and antiemetics, when feasible, to manage constipation 11
• For opioid-induced constipation refractory to laxatives, the National Comprehensive Cancer Network suggests considering peripherally-acting μ-opioid receptor antagonists like methylnaltrexone (0.15 mg/kg subcutaneously every other day) 11
• The National Comprehensive Cancer Network advises against using antispasmodics like alverine as primary constipation treatment, as they relax intestinal smooth muscle and can worsen constipation 11

Management of Buspirone‑Associated Constipation

First‑Line Therapy

• Initiate polyethylene glycol (PEG) 17 g (approximately one heaping tablespoon) mixed in 8 oz of water once daily as the primary treatment for buspirone‑induced constipation; this regimen is endorsed by the American Gastroenterological Association’s 2023 guidelines as the strongest evidence‑based first‑line option for chronic constipation. 12
• Encourage patients to increase fluid intake to at least 2 L per day, especially if baseline consumption is low, to enhance the efficacy of PEG. 12
• Advise regular physical activity to stimulate the gastrocolic reflex and support bowel regularity. 12

Alternative Osmotic Agents (Second‑Line Options)

• If PEG is not tolerated or unavailable, consider adding or substituting other osmotic laxatives such as lactulose, magnesium hydroxide, or magnesium citrate; magnesium‑based agents should be avoided in patients with renal impairment. 13

Prescription Secretagogues (Third‑Line Options for Refractory Cases)

• Linaclotide – a guanylate cyclase‑C agonist that has demonstrated the highest efficacy for constipation, though it may cause diarrhea. 14
• Lubiprostone – a chloride channel activator that is less likely to induce diarrhea compared with linaclotide. 14
• Plecanatide – another guanylate cyclase‑C agonist offering an alternative secretagogue option. 14